🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 21 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 10/06/2014 | 74,30 | 75,23 | 72,79 | 74,04 | -0,76% | 3,28% | 1.307.500 |
| 09/06/2014 | 73,64 | 75,43 | 73,30 | 74,61 | +1,52% | 2,89% | 1.114.000 |
| 06/06/2014 | 73,65 | 73,65 | 72,47 | 73,49 | +0,59% | 1,60% | 1.185.200 |
| 05/06/2014 | 72,63 | 73,45 | 71,61 | 73,06 | +0,58% | 2,53% | 1.397.700 |
| 04/06/2014 | 72,60 | 73,60 | 72,24 | 72,64 | -0,44% | 1,87% | 1.581.900 |
| 03/06/2014 | 71,70 | 72,98 | 71,00 | 72,96 | +0,45% | 2,76% | 975.500 |
| 02/06/2014 | 72,16 | 72,98 | 71,54 | 72,63 | +0,51% | 2,00% | 1.173.000 |
| 30/05/2014 | 72,96 | 72,96 | 71,33 | 72,26 | -0,76% | 2,23% | 1.173.600 |
| 29/05/2014 | 72,31 | 72,96 | 71,42 | 72,81 | +1,52% | 2,13% | 1.321.000 |
| 28/05/2014 | 73,43 | 73,48 | 71,65 | 71,72 | -2,24% | 2,49% | 1.460.300 |
| 27/05/2014 | 72,07 | 73,38 | 71,33 | 73,36 | +3,27% | 2,84% | 1.593.600 |
| 23/05/2014 | 71,51 | 71,85 | 70,01 | 71,04 | -0,20% | 2,57% | 1.118.600 |
| 22/05/2014 | 68,24 | 71,48 | 67,50 | 71,18 | +6,00% | 5,83% | 2.010.700 |
| 21/05/2014 | 65,51 | 67,19 | 65,47 | 67,15 | +2,53% | 2,63% | 1.076.100 |
| 20/05/2014 | 67,28 | 67,43 | 65,06 | 65,49 | -2,57% | 3,52% | 1.071.400 |
| 19/05/2014 | 65,00 | 67,48 | 64,28 | 67,22 | +3,37% | 4,92% | 1.317.200 |
| 16/05/2014 | 65,59 | 66,11 | 63,60 | 65,03 | -0,66% | 3,83% | 2.018.800 |
| 15/05/2014 | 66,69 | 67,48 | 65,02 | 65,46 | -3,29% | 3,69% | 1.538.500 |
| 14/05/2014 | 66,85 | 68,28 | 65,32 | 67,69 | +1,47% | 4,43% | 1.028.800 |
| 13/05/2014 | 67,62 | 67,93 | 66,32 | 66,71 | -1,52% | 2,38% | 827.200 |
| 12/05/2014 | 65,81 | 67,76 | 65,13 | 67,74 | +4,14% | 4,00% | 1.462.700 |
| 09/05/2014 | 63,90 | 65,10 | 62,41 | 65,05 | +1,96% | 4,21% | 1.245.900 |
| 08/05/2014 | 65,13 | 66,14 | 63,46 | 63,80 | -2,10% | 4,11% | 1.309.600 |
| 07/05/2014 | 66,49 | 67,07 | 64,23 | 65,17 | -2,09% | 4,27% | 1.380.900 |
| 06/05/2014 | 68,40 | 68,75 | 66,47 | 66,56 | -2,70% | 3,33% | 1.373.600 |
| 05/05/2014 | 65,41 | 68,50 | 64,81 | 68,41 | +3,07% | 5,64% | 1.467.900 |
| 02/05/2014 | 69,37 | 71,68 | 66,30 | 66,37 | -3,74% | 7,76% | 2.812.400 |
| 01/05/2014 | 67,54 | 69,71 | 66,53 | 68,95 | +1,85% | 4,71% | 1.832.800 |
| 30/04/2014 | 67,27 | 67,99 | 65,94 | 67,70 | +0,19% | 3,05% | 1.466.200 |
| 29/04/2014 | 64,97 | 67,68 | 64,19 | 67,57 | +4,74% | 5,37% | 1.282.200 |